Bank Pictet & Cie Europe AG Has $201,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

Bank Pictet & Cie Europe AG decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 48.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,501 shares of the life sciences company’s stock after selling 1,436 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Illumina were worth $201,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the 4th quarter valued at $32,000. Versant Capital Management Inc lifted its holdings in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. TD Private Client Wealth LLC lifted its holdings in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares during the period. V Square Quantitative Management LLC lifted its holdings in Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after buying an additional 132 shares during the period. Finally, Spire Wealth Management lifted its holdings in Illumina by 26.0% during the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock worth $63,000 after buying an additional 97 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN stock opened at $100.24 on Friday. The firm has a market cap of $15.88 billion, a PE ratio of -13.05 and a beta of 1.10. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The business has a 50 day moving average of $132.74 and a 200-day moving average of $134.74. Illumina, Inc. has a 12-month low of $99.35 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.42 earnings per share for the current year.

Analysts Set New Price Targets

ILMN has been the topic of several recent research reports. Robert W. Baird lifted their target price on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and cut their target price for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Barclays downgraded Illumina from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $130.00 to $100.00 in a report on Monday, February 10th. UBS Group boosted their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley dropped their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.